Skip to main content
Top

Cancer Causes & Control

Issue 6/2002

Content (13 Articles)

A comprehensive worksite cancer prevention intervention: behavior change results from a randomized controlled trial (United States)

Glorian Sorensen, Anne M Stoddard, Anthony D. LaMontagne, Karen Emmons, Mary Kay Hunt, Richard Youngstrom, Deborah McLellan, David C Christiani

Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden)

Annekatrin Lukanova, Stefan Söderberg, Pär Stattin, Richard Palmqvist, Eva Lundin, Carine Biessy, Sabina Rinaldi, Elio Riboli, Göran Hallmans, Rudolf Kaaks

Serum selenium and the risk of cervical cancer among women in the United States

Frances E. Thompson, Blossom H. Patterson, Stephanie J. Weinstein, Mary McAdams, Vickie L. Spate, Richard F. Hamman, Robert S. Levine, Katherine Mallin, Paul D. Stolley, Louise A. Brinton, J. Steven Morris, Regina G. Ziegler

GSTM-1 and NAT2 and genetic alterations in colon tumors

M.L. Slattery, Karen Curtin, K Ma, Donna Schaffer, John Potter, Wade Samowitz

Aspirin, other NSAIDs, and ovarian cancer risk (United States)

Kathleen M. Fairfield, David J. Hunter, Charles S. Fuchs, Graham A. Colditz, Susan E. Hankinson

Breast cancer survival in African American women: Is alcohol consumption a prognostic indicator?

Paige A. Green McDonald, Rosemary Williams, Fitzroy Dawkins, Lucile L. Adams-Campbell

Folate, methionine, alcohol, and colorectal cancer in a prospective study of women in the United States

Andrew Flood, Laura Caprario, Nilanjan Chaterjee, James V. Lacey Jr., Catherine Schairer, Arthur Schatzkin

A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands)

Agnes G. Schuurman, R. Alexandra Goldbohm, Henny A. M. Brants, Piet A. van den Brandt

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine